SciClone in-licenses cancer immunotherapy to pipeline
China-focused SciClone Pharma inked an exclusive licensing agreement with San Diego-based EpicentRx to co-develop and commercialize its cancer immunotherapy for the Chinese market.
Paying EpicentRx an undisclosed amount of upfront payment and up to $120 million in milestone achievements, the now-privatized SciClone will bring the U.S. biotech’s cancer drug RRx-001 to mainland China, Hong Kong, Macau, and Taiwan for liver cancer.
RRx-001 works by downregulating the CD47-SIRPα signaling axis, which is commonly found to be overactive in many types of cancer. The drug normalizes the tumor microenvironment and activates tumor-associated macrophages, sensitizing solid tumors to standard cancer therapies. It is currently in Phase 3 development for treating small cell lung cancer, and has an orphan drug designation for SCLC, neuroendocrine tumors, and glioblastoma.
Paying EpicentRx an undisclosed amount of upfront payment and up to $120 million in milestone achievements, the now-privatized SciClone will bring the U.S. biotech’s cancer drug RRx-001 to mainland China, Hong Kong, Macau, and Taiwan for liver cancer.
RRx-001 works by downregulating the CD47-SIRPα signaling axis, which is commonly found to be overactive in many types of cancer. The drug normalizes the tumor microenvironment and activates tumor-associated macrophages, sensitizing solid tumors to standard cancer therapies. It is currently in Phase 3 development for treating small cell lung cancer, and has an orphan drug designation for SCLC, neuroendocrine tumors, and glioblastoma.
No hay comentarios:
Publicar un comentario